NEW YORK (360Dx) – Rosetta Genomics said that it recorded $330,000 in revenues for the RosettaGX Reveal thyroid miRNA classifier during October, which would represent a $4 million annual revenue run rate. The test classifies indeterminate thyroid nodules. The company said the revenue ramp is partly attributable to record commercial collections driven by increased sample volumes and higher per-claim payments. The test recorded $860,000 in revenues during the third quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.